Igor Genkin, MD
Hematology & Oncology · Salem, OHNPI 1700802972
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $15,095 of the $18,220 with a category attached, or 82.9%. 15 manufacturers reported payments, led by Incyte Corporation at 24.3% of the total. Reporting peaked in 2022 at $10,313 and has fallen 90.4% since, to $986 in 2025.
Across 34 payments — averaging $535.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Incyte Corporation$4K
- GSK$4K
- AstraZeneca$3K
- Morphosys, US Inc.$2K
- Blueprint Medicines Corporation$2K
- Puma Biotechnology, Inc.$1K
- plus $2K from 9 others
Across 22 payments — averaging $57,747 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- BD$1.3M
- Agile Therapeutics, Inc.$1K
What the payments were for
- Consulting fees$15,09583%
- Speaking & faculty fees$1,7129%
- Travel & lodging$5913%
- Food & beverage$6323%
- Education$1901%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Incyte Corporation | 2 | $4,420 |
| GSK | 10 | $4,065 |
| AstraZeneca(2 entities) | 3 | $3,020 |
| Morphosys, US Inc. | 5 | $1,687 |
| Blueprint Medicines Corporation | 1 | $1,512 |
| Puma Biotechnology, Inc. | 3 | $1,201 |
| Daiichi Sankyo Inc. | 1 | $650 |
| Astellas Pharma US Inc | 2 | $600 |
| Swedish Orphan Biovitrum AB | 1 | $425 |
| Cardinal Health 110 LLC | 1 | $275 |
| Amneal Pharmaceuticals LLC | 1 | $210 |
| Johnson & Johnson | 1 | $90 |
| Caris MPI, Inc. | 1 | $24 |
| Genmab U.S., Inc. | 1 | $23 |
| ADC Therapeutics America, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$18,220 in reported general payments places this provider in the 75th percentile of 450 hematology & oncology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TagrissoOsimertinib Mesylate | 13 | $213,880 |
| Abiraterone Acetate | 35 | $59,329 |
| Prochlorperazine Maleate | 31 | $841 |
| Ondansetron Hcl | 28 | $830 |
| Anastrozole | 40 | $581 |
| Letrozole | 37 | $237 |
| Omeprazole | 12 | $151 |
| Prednisone | 25 | $102 |
| Levothyroxine Sodium | 11 | $101 |
| Dexamethasone | 11 | $97 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaTagrisso | $3,020 | $213,88013 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $210 | $10111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 450 hematology & oncology providers in Ohio.
Other hematology & oncology in Salem
- Hillard LazarusCleveland$2M
- Kasra KaramlouSandusky$1.8M
- David WaterhouseCincinnati$1.3M
- Taral PatelColumbus$888K
- Tarek ChidiacColumbus$765K
- Saulius GirniusMontgomery$707K
- Ronald BukowskiCleveland$594K
- Balazs HalmosCleveland$568K
- Jorge GarciaCleveland$513K
- Alejandro CalvoKettering$463K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.